COVID-19
Conditions
Brief summary
This study is a prospective, observational multicentric study. The study population entails adult patients hospitalized with a high clinical suspicion of COVID-19 and consists of two study arms (SARS-CoV2- vs. SARS-CoV2+).This combined fundamental research project has a dual goal: on the one hand assessing immunological predisposing factors for severe infection and investigating the immunological impact of SARS-CoV2 infection, on the other hand studying viral characteristics. Furthermore, a substudy will examine the pharmacokinetics and pharmacodynamics of hydroxychloroquine in patients receiving this antiviral treatment (REVIVE susbstudy). To answer these research questions, samples will be collected from patients with a high clinical suspicion of COVID-19, hospitalized at UZ Gent and 2 participating hospitals in Ghent (AZ Maria Middelares en AZ Jan Palfijn).
Interventions
PROCEDUREBlood draw
8x9mL EDTA tubes. In subjects treated with hydroxychloroquine treatment an extra EDTA tube (4mL) will be collected for the REVIVE substudy.
PROCEDUREBronchoalveolar lavage
Only in case of diagnostic or therapeutic indication.
PROCEDURESARS CoV-2 swabs
Nasopharyngeal, oropharyngeal and nasal swabs
Sponsors
Fund for Scientific Research, Flanders, Belgium
Chan Zuckerberg Initiative
Flanders Institute for Biotechnology
University Hospital, Ghent
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Upper or lower respiratory symptoms and temperature ≥37.5°C, with high clinical suspicion of COVID-19 * Requiring hospitalization
Exclusion criteria
* Known pregnancy at the time of screening * Inability to give informed consent or absence of legal representative who can give informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Identification of cytokines and chemokines associated with COVID-19 severity and outcome. | 6 months | Cytokine and chemokine analysis (U-plex Mesoscale Diagnostics) on the plasma and BAL fluid will be correlated to disease severity and outcome |
| Identification of cellular subsets that can predict COVID-19 severity and outcome. | 6 months | By using high-dimensional flow cytometry on cryopreserved PBMCs, the investigators will assess whether the phenotype and intracellular signaling can predict COVID-19 severity and disease outcome. |
| SARS CoV-2 sequencing. | 6 months | Whole genome sequencing and viral metagenomics analysis will be performed on selected nasopharyngeal swabs and bronchoalveolar lavage fluid. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Single-cell RNA sequencing of BAL fluid and matched PBMC samples. | 6 months | Single -cell RNA sequencing will be performed on fresh BAL fluid and matched PBMCs by using 10X Genomics technology. The aim of the project is to study the transcriptional activity in different immune cells in the lung in COVID-19 patients with differing disease severity and compare these to non-COVID-19 respiratory infections. |
| Analysis of micronutrient Se in plasma samples from COVID-19 + and COVID-19 - patients. | 12 months | Total serum or plasma concentrations (µg/L) of Se will be measured using a benchtop TXRF spectrometer (S4 T-STAR, Bruker Nano GmbH, Berlin, Germany) by prof. Gijs Du Laing and the laboratory of Prof. Lutz Schomburg. |
| Measurement of plasma hydroxychloroquine and N-desethylhydroxychloroquine (REVIVE). | 6 months | In this pilot substudy (REVIVE study), the investigators aim to measure plasma hydroxychloroquine, measuring range 10-2250 ng/mL, and the active metabolite, plasma N-desethylhydroxychloroquine, measuring range 2-2250 ng/m, in patients treated with hydroxychloroquine. |
| Analysis of micronutrients Cu, Fe and Zn in plasma samples from COVID-19 + and COVID-19 - patients. | 12 months | Total serum or plasma concentrations (mg/L) of Cu, Fe and Zn will be measured using a benchtop TXRF spectrometer (S4 T-STAR, Bruker Nano GmbH, Berlin, Germany) by prof. Gijs Du Laing and the laboratory of Prof. Lutz Schomburg. |
Countries
Belgium
Outcome results
None listed